MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is Adlai Nortye Group Ltd. (ANL) Stock Down -8.02% Today?

Why Is Adlai Nortye Group Ltd. (ANL) Stock Down -8.02% Today?

Key Takeaways

  • ANL ADSs fell 8.02% to $8.72 in Wednesday morning trading, extending Tuesday's 5.48% decline.
  • No new company press release, SEC filing, or analyst rating change was issued alongside the move.
  • Positioning ahead of Thursday's plenary AN4035 presentation at the EORTC-NCI-AACR Symposium in Barcelona is a likely contributor, with the talk expected to center on translational and combination data rather than human efficacy results.
  • Structural supply pressure from private-placement shares registered for resale by selling shareholders remains an overhang on the float.
  • The drop came without a matching sector or macro shock, pointing to company-specific and technical drivers.
  • News Significance Score: 17/100 – No verified news, and a move only about twice the stock's typical daily swing.
  • Traders are watching Thursday's presentation for dose, enrollment, and combination detail, along with the $8.62 July low now being tested.
  • More detail on Price Targets, Earnings, and Forecast is available on the dedicated ticker pages.
  • Explore Trending AI Robots to see which automated strategies are performing best in current conditions.

Opening Summary

Adlai Nortye Group Ltd. (ANL) is a clinical-stage oncology company developing RAS-targeting therapies and next-generation cancer immunotherapies, including the oral pan-RAS(ON) inhibitor AN9025, the CEACAM5-targeting antibody-drug conjugate AN4035, and the immunotherapy candidate AN8025. The stock is under pressure on Wednesday: the latest trade at $8.72 puts the ADSs down 8.02%, or $0.76, from Tuesday's close of $9.48, and the decline accelerated after a 5.48% drop in the prior session. No verified news release, filing, or sell-side action explains the move. The drivers are instead structural and behavioral: an unresolved resale overhang, pre-event de-risking ahead of a key scientific presentation, and a stock that remains deep in a corrective phase below all major moving averages.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found behind Wednesday's decline. The company has issued no release since 27 October, when it announced the AN4035 oral presentation slot in Barcelona; there has been no new SEC filing, no financing announcement, and no change to analyst ratings or targets in the past week. The most recent published action was a reiterated Buy rating with a $20 target on 9 November. With no fresh information, the decline is most consistent with a continuation of the de-risking that began in mid-October, when the stock broke down from the $15–$16 area. That move has been persistent and orderly rather than event-driven: the shares are now about 49% below their 52-week high of $17.25 and sit beneath their 50-day average near $12.80 and 200-day average near $11.75.

Pre-Event Positioning Ahead of the Barcelona Plenary

Investors have been trimming exposure into a scheduled catalyst rather than reacting to one. Dr. Archie Tse, President and Head of R&D, is due to deliver an oral presentation on AN4035 on 19 November at the 38th EORTC-NCI-AACR Symposium, a plenary session focused on RAS pathway targeting. Expectations had built around the event since the late-breaking abstract was announced on 27 October. The company, however, has signposted that the talk will cover translational and EGFR-combination data from the ongoing Phase I study, with first human efficacy data not anticipated until the second half of 2027. Against a competitive pan-RAS field, a presentation light on clinical outcomes gives holders little room for a positive surprise — a setup classically associated with selling ahead of the event and re-entering afterward.

Resale Registration and Float Dynamics

A second, slower-moving weight is the resale registration covering ADSs underlying shares sold in the February and April 2026 private placements, which raised roughly $140 million and $150 million respectively and left a large block of stock registered for resale by selling shareholders. Shares outstanding rose about 49% quarter over quarter, and buyers from those placements have been free to distribute into strength. That supply is a genuine structural headwind for a small-cap biotech whose float is roughly 49.6 million ADSs against a market capitalization of about $560 million. Short interest of approximately 5.8 million shares, or 8.7% of shares outstanding, adds further asymmetry to daily swings.

Market Context and Trading Activity

Turnover in the early session ran modestly below the pace needed to match recent daily averages of roughly 230,000 to 290,000 ADSs, suggesting thin liquidity rather than institutional liquidation — a modest order book can move a $9 stock several percentage points. The decline is idiosyncratic: no regulatory, reimbursement, or clinical setback across the biotechnology complex coincided with the timing, and the move is not traceable to a broad macro release. Technically, the shares have broken below the November floor around $9.37 and are testing the July intraday low of $8.62, with a 14-day relative strength reading that had already slipped into the high 30s before today's session.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. This event registers 17 out of 100. There was no verifiable fundamental catalyst, and the only substantive corporate developments — the conference abstract and the Lilly and Merck KGaA cetuximab collaboration — were disclosed weeks ago and are already reflected in the price. The price component is similarly restrained: an 8.02% decline is roughly 1.9 times the stock's average absolute daily move of about 4.2% over the last 60 sessions, and moves of that size or larger occurred nine times in that window. Weak news plus a large-but-not-rare swing produces a low score.

What Comes Next for ANL

Thursday's plenary session is the near-term focal point; disclosures on dose escalation, enrollment progress in Australia, the U.S., and China, and the rationale for combining AN4035 with cetuximab will shape sentiment into year-end. Beyond Barcelona, management has guided to completing Phase I dose escalation for AN8025 by the end of 2026, with first patient dosing for AN4035 targeted for the second half of 2026 and initial Phase Ia AN9025 data alongside Phase II ARTEMIS topline results expected in the first half of 2027. The next scheduled financial update is the full-year 2026 report, expected in early 2027. Analysts remain uniformly constructive, with a consensus Strong Buy and a wide $20 to $49 target range. Risks include further resale-related supply, a cash balance of about $232 million that must fund several parallel programs, the possibility of additional financing, and the long gap before human efficacy readouts.

Trending AI Robots

Tickeron's Trending AI Robots page is a curated view of the platform's strongest automated trading strategies under present market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but this section surfaces only those currently posting the most convincing results. Bots differ widely by strategy logic, holding period, performance metrics, and the specific symbols they trade, so the lineup changes as market conditions shift. For readers tracking volatile small-cap names like this one, it is a practical starting point for comparing approaches — explore the page to see which robots are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ANL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ANL in -10.65% downward trend, declining for three consecutive days on November 17, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ANL declined for three days, in 135 of 148 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANL as a result. In 63 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The 10-day moving average for ANL crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ANL entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANL's RSI Indicator exited the oversold zone, 14 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 30 cases where ANL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for ANL just turned positive on November 06, 2026. Looking at past instances where ANL's MACD turned positive, the stock continued to rise in 23 of 26 cases over the following month. The odds of a continued upward trend are 88%.

Following a +15.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANL advanced for three days, in 121 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ANL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.082) is normal, around the industry mean (3.592). P/E Ratio (-15.576) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (33.784) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ANL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3